Call Now

Human CD160 Protein (His Tag)

BY55,NK1,NK28

Catalog Number P12191-H08H
Organism Species Human
Host Human Cells
Synonyms BY55,NK1,NK28
Molecular Weight The recombinant human CD160 consists of 143 amino acids and has a predicted molecular mass of 16.4 kDa. In SDS-PAGE under reducing conditions, rh CD160 migrates as an approximately 25 kDa band due to glycosylation.
predicted N Ile 27
SDS-PAGE
Purity > 90 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the human CD160 (NP_008984.1) (Met 1-Leu 158) without the propeptide was expressed, with a polyhistidine tag at the C-terminus.
Bio-activity Measured by its ability to bind with biotinylated human HVEM-Fch (P10334-H03H) in a functional ELISA.
Research Area Immunology |Adaptive Immunity |Costimulation & Costimulatory Molecule |Other Costimulatory Molecules
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background CD160 antigen, also known as Natural killer cell receptor BY55 and CD160, is a cell membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. CD160 is a GPI-anchored lymphocyte surface receptor in which expression is mostly restricted to the highly cytotoxic CD56(dim)CD16(+) peripheral blood NK subset. CD160 is a receptor showing broad specificity for both classical and non-classical MHC class I molecules. CD160 is expressed in spleen, peripheral blood, and small intestine. Expression of CD160 is restricted to functional NK and T cytotoxic lymphocytes. CD160 acts as a co-activator receptor for CD3-induced proliferation of CD4+ CD160+ T cells isolated from inflammatory skin lesions. Unique CD4+ CD160+ lymphocyte subset may play a role in the pathogenesis of skin inflammation. Activated NK lymphocytes release a soluble form of CD160 that functionally impairs the MHC-I-specific cytotoxic CD8(+) T lymphocyte responsiveness.
Reference
  • Barakonyi A. et al., 2004, J Immunol.173 (9): 5349-54.
  • Rabot M. et al., 2006, Transpl Immunol. 17 (1): 36-8.
  • Abecassis S. et al., 2007, J Invest Dermatol. 127?(5): 1161-6.
  • Giustiniani J.?et al., 2007, J Immunol. 178 (3): 1293-300.